Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Taslim Ahmed Al-Hilal, Ph.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rashid J, Alobaida A, Al-Hilal TA, Hammouda S, McMurtry IF, Nozik-Grayck E, Stenmark KR, Ahsan F. Repurposing rosiglitazone, a PPAR-? agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH. J Control Release. 2018 06 28; 280:113-123. PMID: 29723610.
    Citations:    
  2. Kadry H, Al-Hilal TA, Keshavarz A, Alam F, Xu C, Joy A, Ahsan F. Multi-purposable filaments of HPMC for 3D printing of medications with tailored drug release and timed-absorption. Int J Pharm. 2018 Jun 10; 544(1):285-296. PMID: 29680281.
    Citations:    
  3. Seo J, Al-Hilal TA, Jee JG, Kim YL, Kim HJ, Lee BH, Kim S, Kim IS. A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots. Nanomedicine. 2018 04; 14(3):633-642. PMID: 29309907.
    Citations:    
  4. Choi JU, Chung SW, Al-Hilal TA, Alam F, Park J, Mahmud F, Jeong JH, Kim SY, Byun Y. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway. Biomaterials. 2017 Sep; 139:56-66. PMID: 28586719.
    Citations:    
  5. Haque MR, Kim J, Park H, Lee HS, Lee KW, Al-Hilal TA, Jeong JH, Ahn CH, Lee DS, Kim SJ, Byun Y. Xenotransplantation of layer-by-layer encapsulated non-human primate islets with a specified immunosuppressive drug protocol. J Control Release. 2017 07 28; 258:10-21. PMID: 28433740.
    Citations:    
  6. Park J, Jeon OC, Yun J, Nam H, Hwang J, Al-Hilal TA, Kim K, Kim K, Byun Y. Correction to End-Site-Specific Conjugation of Enoxaparin and Tetradeoxycholic Acid Using Nonenzymatic Glycosylation for Oral Delivery. J Med Chem. 2017 01 12; 60(1):524-525. PMID: 28005363.
    Citations:    
  7. Park J, Jeon OC, Yun J, Nam H, Hwang J, Al-Hilal TA, Kim K, Kim K, Byun Y. End-Site-Specific Conjugation of Enoxaparin and Tetradeoxycholic Acid Using Nonenzymatic Glycosylation for Oral Delivery. J Med Chem. 2016 12 08; 59(23):10520-10529. PMID: 27933952.
    Citations:    
  8. Al-Hilal TA, Chung SW, Choi JU, Alam F, Park J, Kim SW, Kim SY, Ahsan F, Kim IS, Byun Y. Targeting prion-like protein doppel selectively suppresses tumor angiogenesis. J Clin Invest. 2016 Apr 01; 126(4):1251-66. PMID: 26950422.
    Citations:    
  9. Alam F, Al-Hilal TA, Park J, Choi JU, Mahmud F, Jeong JH, Kim IS, Kim SY, Hwang SR, Byun Y. Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate). Biomaterials. 2016 Apr; 86:56-67. PMID: 26890038.
    Citations:    
  10. Alam F, Hwang SR, Al-Hilal TA, Chung SW, Kim HS, Kang BH, Zhang HS, Shin SH, Lee JY, Kang MS, Kwon GH, Jeon OC, Kim SY, Byun Y. Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models. Drug Dev Ind Pharm. 2016 Aug; 42(8):1247-57. PMID: 26612099.
    Citations:    
  11. Al-Hilal TA, Chung SW, Alam F, Park J, Lee KE, Jeon H, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Corrigendum: Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci Rep. 2015 Aug 05; 5:9407. PMID: 26244565.
    Citations:    
  12. Park J, Al-Hilal TA, Jeong JH, Choi Ju, Byun Y. Design, Synthesis, and Therapeutic Evaluation of Poly(acrylic acid)-tetraDOCA Conjugate as a Bile Acid Transporter Inhibitor. Bioconjug Chem. 2015 Aug 19; 26(8):1597-605. PMID: 26086474.
    Citations:    
  13. Park J, Jeong JH, Al-Hilal TA, Kim JY, Byun Y. Size Controlled Heparin Fragment-Deoxycholic Acid Conjugate Showed Anticancer Property by Inhibiting VEGF165. Bioconjug Chem. 2015 May 20; 26(5):932-40. PMID: 25894217.
    Citations:    
  14. Mahmud F, Jeon OC, Al-Hilal TA, Kweon S, Yang VC, Lee DS, Byun Y. Absorption Mechanism of a Physical Complex of Monomeric Insulin and Deoxycholyl-l-lysyl-methylester in the Small Intestine. Mol Pharm. 2015 Jun 01; 12(6):1911-20. PMID: 25892399.
    Citations:    
  15. Shin JY, Jeong JH, Han J, Bhang SH, Jeong GJ, Haque MR, Al-Hilal TA, Noh M, Byun Y, Kim BS. Transplantation of heterospheroids of islet cells and mesenchymal stem cells for effective angiogenesis and antiapoptosis. Tissue Eng Part A. 2015 Mar; 21(5-6):1024-35. PMID: 25344077.
    Citations:    
  16. Kim JY, Al-Hilal TA, Chung SW, Kim SY, Ryu GH, Son WC, Byun Y. Antiangiogenic and anticancer effect of an orally active low molecular weight heparin conjugates and its application to lung cancer chemoprevention. J Control Release. 2015 Feb 10; 199:122-31. PMID: 25523032.
    Citations:    
  17. Alam F, Al-Hilal TA, Chung SW, Park J, Mahmud F, Seo D, Kim HS, Lee DS, Byun Y. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy. J Control Release. 2015 Jan 10; 197:180-9. PMID: 25445701.
    Citations:    
  18. Chung SW, Bae SM, Lee M, Al-Hilal TA, Lee CK, Kim JK, Kim IS, Kim SY, Byun Y. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways. Biomaterials. 2015 Jan; 37:271-8. PMID: 25453957.
    Citations:    
  19. Al-Hilal TA, Alam F, Park JW, Kim K, Kwon IC, Ryu GH, Byun Y. Prevention effect of orally active heparin conjugate on cancer-associated thrombosis. J Control Release. 2014 Dec 10; 195:155-61. PMID: 24862320.
    Citations:    
  20. Alam F, Al-Hilal TA, Chung SW, Seo D, Mahmud F, Kim HS, Kim SY, Byun Y. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials. 2014 Aug; 35(24):6543-52. PMID: 24816287.
    Citations:    
  21. Al-Hilal TA, Chung SW, Alam F, Park J, Lee KE, Jeon H, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Functional transformations of bile acid transporters induced by high-affinity macromolecules. Sci Rep. 2014 Feb 25; 4:4163. PMID: 24566561.
    Citations:    
  22. Al-Hilal TA, Park J, Alam F, Chung SW, Park JW, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin. J Control Release. 2014 Feb 10; 175:17-24. PMID: 24333628.
    Citations:    
  23. Jeon OC, Hwang SR, Al-Hilal TA, Park JW, Moon HT, Lee S, Park JH, Byun Y. Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates. Pharm Res. 2013 Apr; 30(4):959-67. PMID: 23292220.
    Citations:    
  24. Al-Hilal TA, Alam F, Byun Y. Oral drug delivery systems using chemical conjugates or physical complexes. Adv Drug Deliv Rev. 2013 Jun 15; 65(6):845-64. PMID: 23220326.
    Citations:    
  25. Hwang SR, Seo DH, Al-Hilal TA, Jeon OC, Kang JH, Kim SH, Kim HS, Chang YT, Kang YM, Yang VC, Byun Y. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis. J Control Release. 2012 Nov 10; 163(3):374-84. PMID: 23041275.
    Citations:    
  26. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Jin SJ, Moon HT, Yang VC, Kim SY, Byun Y. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. J Control Release. 2010 Dec 20; 148(3):317-26. PMID: 20869408.
    Citations:    
  27. Eom JS, Koh KS, Al-Hilal TA, Park JW, Jeon OC, Moon HT, Byun Y. Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats. Thromb Res. 2010 Sep; 126(3):e220-4. PMID: 20619883.
    Citations:    
  28. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Moon HT, Kim CY, Byun Y. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative. Mol Pharm. 2010 Jun 07; 7(3):836-43. PMID: 20349950.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Al-Hilal's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (186)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.